Consensus Hoth Therapeutics, Inc.

Equities

HOTH

US44148G2049

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-10 EDT			5-day change	1st Jan Change
1.17 ^USD	-2.48%		-3.29%	-18.74%

03-28	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Evolution of the average Target Price on Hoth Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

406c195a7fd0b0.rXrAZMovjvCI9nYSHllIDNtvU356mQNAvxuNNBFVci0.3SytEr9f95fdgT5beAZ5T4NWJTUOwDYB7E_lc2YzKmLbA5EorFnqhOqjFQ~c67a82932e09ff16176d2021732498d7

Analyst Recommendations on Hoth Therapeutics, Inc.

HC Wainwright Starts Hoth Therapeutics With Buy Rating, $4 Price Target	02-05	MT
EF Hutton Cuts Hoth Therapeutics Price Target to $7.50 From $12, Maintains Buy Rating	23-09-14	MT
EF Hutton Assumes Hoth Therapeutics at Buy With $14 Price Target	23-08-23	MT
Fed Rate Decision Eyed Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	23-06-14	MT
EF Hutton Lowers Price Target on Hoth Therapeutics to $14 From $33, Maintains Buy Rating	23-04-03	MT
EF Hutton Lowers Hoth Therapeutics' Price Target to $33 From $45, Keeps Buy Rating	22-12-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.17 USD

Average target price

5.5 USD

Spread / Average Target

+370.01%

High Price Target

7 USD

Spread / Highest target

+498.19%

Low Price Target

4 USD

Spread / Lowest Target

+241.82%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Hoth Therapeutics, Inc.

HC Wainwright
EF Hutton

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar